Mitiglinide is potentially best-in-class with key clinical advantages.
Mitiglinide softens existing drawbacks of other glinides
Stronger affinity for SUR1 in pancreatic B-cells
Less GI and cardiovascular side effects
Mitiglinide strengthens existing advantages of glinides
Improve dyslipidemia condition
Lower risk of post prandial hypoglycaemia (suitable for eldery)
Mitiglinide as an insulinotropic agent plays a major role in current T2D treatment.